A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about Aprea Therapeutics Inc’s (APRE) stock grades for Value, Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
| Share Statistics | APRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.3 | $288.9 | 6% |
|
| Shares Out (Mil) | 53.5 | 54.0 | 49% |
|
| Institutional Ownership | 54.7% | 93.1% | 37% |
|
| Float (Mil) | 7.9 | 41.4 | 16% |
|
| Beta | 1.59 | 0.94 | 85% |
|
| Avg Daily Volume (000s) | 1,047 | 480 | 73% |
|
| Price Change (52-week) |
(47.8%) | 59.9% | 16% |
|
| Growth | APRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 25.1% | (10.1%) | 80% |
|
| EPS (5yr) | 48.0% | 15.9% | 92 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 49.6% | (15.6%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.073) | ($0.313) | ($0.290) | |
| Month Ago EPS | ($0.230) | ($0.830) | ($0.790) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.230) | ($0.830) | ($0.790) | |
| Year/Year Chg | 9.0% | (83.8%) | (85.3%) | |
| Financials | APRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($43) | 27% |
|
| EPS (TTM) | ($0.597) | ($1.500) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($32) | $190 | 1% |
|
| Valuation | APRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.26 | 2.84 | 4% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | APRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (41.3%) | (47.7%) | 13% |
|
| ROE | (47.4%) | (55.0%) | 16% |
|
| Liabilities to Assets | 7.3% | 29.6% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Aprea Therapeutics, Inc. did not pass any screens on 9/2/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
